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A bioanalytical method was developed and applied to quantify the free imipenem concentrations for 
pharmacokinetics and PK/PD correlation studies of the dose adjustments required to maintain antimicrobial 
effectiveness in pediatric burn patients. A reverse-phase Supelcosil LC18 column (250 x 4.6 mm 5 micra), 
binary mobile phase consisting of 0.01 M, pH 7.0 phosphate buffer and acetonitrile (99:1, v/v), flow 
rate of 0.8 mL/min, was applied. The method showed good absolute recovery (above 90%), good 
linearity (0.25-100.0 µg/mL, r2=0.999), good sensitivity (LLOQ: 0.25 µg/mL; LLOD: 0.12 µg/mL) and 
acceptable stability. Inter/intraday precision values were 7.3/5.9%, and mean accuracy was 92.9%. A 
bioanalytical method was applied to quantify free drug concentrations in children with burns. Six pediatric 
burn patients (median 7.0 years old, 27.5 kg), normal renal function, and 33% total burn surface area 
were prospectively investigated; inhalation injuries were present in 4/6 (67%) of the patients. Plasma 
monitoring and PK assessments were performed using a serial blood sample collection for each set, 
totaling 10 sets. The PK/PD target attained (40%T>MIC) for each minimum inhibitory concentration 
(MIC: 0.5, 1.0, 2.0, 4.0 mg/L) occurred at a percentage higher than 80% of the sets investigated and 
100% after dose adjustment. In conclusion, the purification of plasma samples using an ultrafiltration 
technique followed by quantification of imipenem plasma measurements using the LC method is quite 
simple, useful, and requires small volumes for blood sampling. In addition, a small amount of plasma 
(0.25 mL) is needed to guarantee drug effectiveness in pediatric burn patients. There is also a low risk of 
neurotoxicity, which is important because pharmacokinetics are unpredictable in these critical patients 
with severe hospital infection. Finally, the PK/PD target was attained for imipenem in the control of 
sepsis in pediatric patients with burns.
Uniterms: Imipenem/quantification. Antibiotics/dosage. Pediatric patients/burn/antibiotics use. High 
Performance Liquid Chromatography/quantitative analysis. Drug plasma monitoring. PK/PD.
Desenvolveu-se e aplicou-se método bioanalítico para quantificar concentrações de imipenem livre para 
estudos de farmacocinética (PK) e de correlação PK/PD dos ajustes de dose requeridos para manter a 
efetividade antimicrobiana em pacientes pediátricos queimados. Utilizou-se coluna Supelcosil LC18 
(250 x 4,6 mm 5 micra), fase móvel binária, consistindo de tampão fosfato 0,01M pH 7,0 e acetonitrila 
(99:1, v/v) e fluxo de 0,8 mL/min. O método mostrou boa recuperação absoluta (acima de 90%), boa 
linearidade (0,25-100,0 µg/mL, r2=0.999), boa sensibilidade (LLOQ: 0,25 µg/mL; LLOD: 0,12 µg/mL)  
e estabilidade aceitável. Os valores de precisão inter/intradia foram 7,3/5,9% e a exatidão média foi 
de 92,9%. O método bioanalítico foi aplicado para quantificar concentrações de fármaco livre em 
crianças com queimaduras, Seis pacientes pediátricos queimados (idade média de 7,0 anos, 27,5 kg), 
com função renal normal e 33% da superfície total queimada foram investigados prospectivamente. 
Lesões por inalação estavam presentes em 4/6 (67%) dos pacientes. O monitoramento plasmático e a 
as avaliações de PK foram efetuadas utilizando coleção de amostras seriais de sangue para cada série, 
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totalizando 10 conjuntos. O alvo PK/PD alcançado (40%T>MIC) para cada concentração inibitória 
mínima (MIC: 0,5, 1,0, 2,0, 4,0 mg/L) ocorreu em porcentagem maior do que 80% dos conjuntos 
investigados e 100% após o ajuste de dose. Em conclusão, a purificação das amostras do plasma usando 
técnica de ultrafiltração seguida de quantificação das medidas do imipenem no plasma usando método 
de cromatografia líquida é bastante simples, útil e necessita de pequenos volumes para as amostras de 
sangue. Além disso, pequena quantidade de plasma (0,25 mL) é necessário para garantir a efetividade 
do fármaco nos pacientes pediátricos queimados. Há, ainda, baixo risco de neurotoxicidade, o que é 
importante, visto que as farmacocinéticas são imprevisíveis nesses pacientes críticos, com grave infecção 
hospitalar. Finalmente, o alvo PK/PD foi alcançado para o imipenem no controle da sepse em pacientes 
pediátricos com queimaduras.
Unitermos: Imipenem/quantificação. Antibióticos/dosagem. Pacientes pediátricos/queimaduras/uso de 
antibióticos. Cromatografia líquida de alta eficiência/análise quantitativa. Monitoramento plasmático. 
PK/PD.
INTRODUCTION
Imipenem is a broad-spectrum carbapenem agent 
that has been widely used to treat life-threatening 
infections in critically ill and burn patients (Belzeberg 
et al., 2004). Imipenem has been shown to have dose-
independent kinetics in male adult patients with preserved 
renal function, and its biological half-life of approximately 
one hour is a function of fast excretion of the drug by the 
kidneys (Drusano et al., 1984; Belzeberg et al., 2004; 
Zhanel et al., 2007).
In a burn injury, several factors may affect a drug’s 
PK, such as the extension of area affected, depth of the 
burn, the presence of sepsis, the degree of hydration, serum 
protein concentrations, age, creatinine clearance (CLcr) and 
the time since the injury (Weinbren, 1999; Blanchet et al, 
2008). Patients with major burns have shown a reduction 
of antimicrobial activity resulting from PK alterations 
due to the extensive hydration and physiological changes 
following the burn injury (Fry, 1996). However, few 
clinical studies have examined imipenem prescribed 
to pediatric patients with burns to control infection 
with Gram negative pathogens and have provided data 
related to PK. A thorough understanding of imipenem 
pharmacokinetics in pediatric patients is important for 
optimizing imipenem dosing regimens to guarantee drug 
effectiveness in controlling infection against nosocomial 
pathogens (Belzeberg et al., 2004).
A survey of the literature has revealed several 
analytical methods to determine imipenem in biological 
fluids using high-cost procedures, including LC-MS/
MS (Xu et al., 2009) and capillary zone electrophoresis 
(Taniguchi et al., 1999) or methods that rely on low-cost 
and very simple microbiological assays with quite low 
specificities (Pietroski et al., 1991).
Then, the aim of the present study was to develop and 
to validate a simple bioanalytical liquid chromatographic 
method to determine imipenem in plasma according 
to FDA guidelines (FDA, 2001) for pharmacokinetics 
and PK/PD correlation studies that focus on the dose 
adjustments required to ensure antimicrobial effectiveness 
in pediatric burn patients.
MATERIAL AND METHODS
Reagents and chemicals
Drug standards of imipenem and ceftriaxone 
(internal standard) and 3-(N-morpholino)-propane 
sulphonic acid (MOPS) were purchased from Sigma 
(St. Louis, MO, USA). All solvents (LC grade) and 
reagents for drug plasma purification and LC analysis were 
purchased from Merck (Darmstadt, Germany). Purified 
water was obtained from Millipore Simplicity System 
(Milford, MA, USA).
LC system
The chromatographic system consisted of a 
Shimadzu model LC-10AVP solvent delivery module 
(Kyoto, Japan) equipped with a SCL-10AVP controller/
software Class VP, autosampler model SIL-10ADVP and 
a detector UV-VIS model SPD-10ADPV. The peak area 
ratio of imipenem to its internal standard was integrated 
using Class VP/computer Intel Celeron software. The 
analytical column was a Supelcosil LC18, 250 x 4.6 mm, 
5 µm (Supelco, Bellefonte, PA, USA) connected to a Nova 
Pak C18 guard column (Waters Assoc., Milford, USA).
The binary mobile phase was freshly prepared on the 
day of its use from a mixture of 0.01 M phosphate buffer 
pH 7.0 that had been previously filtered through a 0.45 
mm filter and acetonitrile (99:01, v/v), which was helium 
degassed for one minute. The chromatographic analysis 
was performed using an isocratic system at a flow rate of 
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0.8 mL/min at room temperature. The injection volume 
was 5 mL, and the effluent was monitored at 300 nm. 
A run time of 15 minutes was required to guarantee the 
selectivity of chromatographic analysis.
Preparations of standards and internal controls
The standard stock solution was prepared by 
dissolving the appropriate amount of imipenem standard 
(10 mg), which was accurately weighted in the 5 mL 
volumetric flask with purified water, to reach a final 
drug concentration of 1.0 mg/mL. The standards were 
prepared to obtain 100.0, 50.0, 20.0, 10.0, 5.0, 2.0, 1.0, 0.5, 
0.25 mg/mL of imipenem by adding the appropriate amount 
of stock drug standard solution to a stock solution of 
drug-free fetal bovine serum (blank serum) and 0.5 mL 
of a mixture containing 0.5 M MOPS-ethylene glycol 
aqueous solution. Linearity was investigated in the range 
of 0.25-100.0 mg/mL, and the calibration curve was 
constructed daily. Additionally, internal controls were 
prepared by diluting the stock solution with a drug-free 
fetal bovine blank serum to obtain the high (80 mg/mL), 
medium high (40 mg/mL), medium low (4.0 mg/mL) and 
low (1.0 mg/mL) concentrations and stored until assay in 
a deep freezer at -80 °C.
The internal standard (IS) was ceftriaxone, and the 
stock solution was prepared in purified water to obtain 
1 mg/mL and kept at -80 °C until assay. The working 
solution of the internal standard was freshly prepared 
by diluting the stock solution with water to reach the 
100 mg/mL drug concentration.
Sample ultrafiltration plasma purification 
procedure
Drug plasma measurements were performed by 
high performance liquid chromatography, requiring the 
addition 0.25 mL plasma to a mixture containing 0.5 M 
MOPS-ethylene glycol aqueous solution (1:1, v/v) and 
the internal standard (10 µg/assay), followed by a protein 
removal procedure prior to HPLC analysis. Purification 
of the plasma samples required a Amicon Ultra - 0.5 mL 
Ultracel 30k centrifugal filter device (Merck-Millipore 
Corporation, USA) to provide fast ultrafiltration during 
spinning at 8,000 g, 4 °C on a centrifuge with a fixed-angle 
rotor for 10 minutes. A filter device with the capacity for 
high concentration factors and easy concentrate recovery 
from dilute and complex sample matrices with 30K cut-
offs (30,000 NMWL: nominal molecule weight limit) 
was applied. After centrifugation, a 0.20 mL volume of 
the fluid protein removed from the filtrate collection tube 
was transferred to a 1 mL vial containing a microvial/vial 
insert for drug analysis in the autosampler.
Linearity, calibration curve and calculation 
procedures
The calibration curve was obtained by plotting 
the peak area ratio obtained for imipenem to its internal 
standard as a function of drug plasma concentration and 
nominal values. The linear regression curve was obtained 
using the following equation: y = a + bx, where (x) is 
the drug concentration, (y) the peak area ratio (a) the 
intercept and (b) the slope. The calibration curve was 
accepted for the linear coefficient of determining the 
estimated (r2>0.99) and systematic error (SE%) lower 
than 15% for all standards with the exception of the 
lower limit of quantifications (LOQ: SE<20%). The 
parameter can be estimated by the value of the mean 
back-calculated concentrations divided by theoretical 
concentrations, expressed as a percentage. Additionally, at 
least six calibrators were considered to construct the daily 
calibration curve 0.25-100.0 mg/mL, and the daily curve 
was accepted if at least 6/8 of the internal controls (high, 
medium and low concentrations analyzed in duplicate) 
presented with a systematic error lower than 15%. At least 
one control of each concentration was required to be within 
the acceptable variation. Once accepted, the calibration 
curve was applied to estimate drug plasma concentration 
in plasma samples collected from the patient. The linearity 
of the bioanalytical method was determined in triplicate 
for each concentration ranging from 0.25 to 100.0 mg/mL.
Accuracy, precision and recovery
The precision of the bioanalytical method was 
expressed by relative standard deviation as a percentage 
(RSD). The intra-day precision was evaluated by 
analyzing the three replicates for the high (80 mg/mL), 
medium high (40 mg/mL), medium low (4.0 mg/mL) and 
low (1.0 mg/mL) concentrations. The inter-day precision 
was determined by analyzing the three replicates for the 
high, medium and low concentrations of imipenem on 
three different days (n=27).
Accuracy was evaluated in three different 
concentrations by analyzing the triplicates and was 
expressed as the percentage of inaccuracy. The intra-
day accuracy was evaluated by analyzing the three 
replicates of the high, medium high, medium low and low 
concentrations. The inter-day accuracy was determined by 
analyzing the three replicates of the high, medium and low 
concentrations of imipenem on three different days (n=27).
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The absolute recovery values for imipenem and the 
internal standard from plasma, expressed as percentage, 
were estimated by the peak area integrated for each drug 
(10 replicates each) in plasma, assayed according to the 
described procedure, versus the peak area integrated for 
each drug after direct injection when considering the same 
nominal drug concentration. The efficiency of the relative 
recovery was estimated by the peak area ratio integrated 
for the analyte and its internal standard (10 replicates), 
assayed according to the described procedure, versus 
the peak area ratio integrated for the drug and its internal 
standard after direct injection.
Specificity
The specificity of the bioanalytical method and the 
ability to accurately measure an analyte in the presence 
of endogenous compounds were evaluated by analyzing 
samples in drug-free plasma (normal, hemolyzed and 
lipemic plasma samples) by applying the previously 
introduced procedure; the retention times of endogenous 
compounds were compared with those obtained for 
imipenem and the internal standard in normal plasma 
extract.
Limit of detection and limit of quantification
The lower limits of detection (LLOD) and of 
quantification (LLOQ) were determined based on the 
analysis of ten replicates for each parameter considered. 
The LLOQ was defined as the lowest drug plasma 
concentration of the calibration daily curve that could be 
determined with an accuracy of 80-120% and precision 
lower than 20%.
Stability study
Spiked blank plasma was analyzed by LC after 
three freezing/thawing cycles considering three different 
concentrations (1.0, 40, 80 mg/mL) analyzed in triplicate by 
applying the analytical procedure as detailed above. Data 
were represented by the systematic error, expressed as a 
percentage. The acceptance criterion for all concentrations 
studied and adopted was lower than the 15% variation 
expressed by the systematic error.
Therapeutic drug monitoring and 
pharmacokinetics of imipenem in burned children
The clinical protocol was a prospective, open-label 
study approved by the Ethical Committee (Protocol 
nº 0069/09) of Hospital das Clínicas, Medical School, 
University of Sao Paulo. The study was conducted 
from April 2009 to March 2013, and informed written 
consent was obtained from all legally designated patient 
representatives.
Pediatric patients up to 10 years old from the Burn 
Intensive Care Unit (ICU), presenting with severe thermal 
injuries and a sepsis diagnosis (clinical and laboratorial) 
(Greenhalgh et al., 2007) were eligible for inclusion. 
Patients with imipenem intolerance or significant renal 
impairment were excluded. The study was based on 
imipenem treatment for suspected or documented gram-
negative nosocomial infections. Initially, the patients 
were treated four times a day with systemic imipenem 
(2 g daily) through a 30-minute infusion every 6 hours 
according to the institutional protocol.
Complete medical histories, physical examinations, 
microbiological profile and laboratory data were obtained 
for each enrolled patient. Creatinine clearance was 
estimated by Schwartz’s method (Schwartz et al., 1976). 
Individual demographic and clinical characteristics are 
shown in Table I.
Patient blood samples were obtained by a venous 
catheter after achieving steady state, with a time point 
periodicity equal to at least five elimination half-lives. 
After drug infusion, serial blood samples (1 mL) were 
collected into sodium EDTA tubes for drug plasma assay 
at 1, 2, 3, 4 and 6 hours. During the patients’ stay in the 
ICU, imipenem pharmacokinetics were investigated 
weekly or when a re-infection by imipenem-sensitive 
strains occurred.
Imipenem plasma concentration-time data were 
analyzed using PK Solutions 2.0 software (Summit, 
USA), and the area under the curve at the time/dose 
interval (AUCssτ), the elimination rate constant (Kel), the 
biological half-life (t(1/2)β), the plasma clearance (CLT) 
and the volume of distribution (Vdss) were estimated. 
Antimicrobial susceptibility expressed by the minimum 
inhibitory concentration (MIC) was obtained from 
the confirmed data after strain documentation by the 
Microbiological laboratory/Central Laboratory by VITEK 
micro diffusion technique plus an automated method 
according to Clinical Laboratory Standards Institute (CLSI 
M100). When any strain was documented by the hospital 
Central Laboratory in time, PK/PD was estimated based 
on MIC data obtained from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST, 2013). 
PK/PD data were based on the 40% fT>MIC for each 
patient investigated; then, the targets for the control of 
infection and drug effectiveness against strains with MIC 
values of 0.5, 1.0, 2.0 and 4.0 mg/L were based on drug 
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TABLE I - Demographic and clinical characteristics of paediatric burn patients after thermal injury: individual and population data 
(n=6)
Patient 
allocation
Gender
Age 
(yrs)
Weight (kg)
BMI 
(kg/m2)
TBSA 
(%)
CLcr (mL/
min)
Inhalation 
injury
Endotracheal 
intubation
Vasoactive 
Drugs
Outcome
#1 M 09 30 17.1 30 207.4 (-) (-) (-) Survivor
#2 F 06 25 19.4 75 185.4 (+) (+) (+) Nonsurvivor
#3 M 02 12 14.8 15 682.0 (+) (+) (-) Survivor
#4 M 01 16 25.0 28 702.2 (-) (-) (-) Survivor
#5 M 08 40 23.7 45 388.1 (+) (+) (+) Survivor
#6 M 03 16 17.7 36 372.8 (+) (+) (+) Survivor
Patients 5M/1F NAP NAP NAP NAP NAP 4/6 4/6 3/6 5/6
Median NAP 7.0 27.5 21.5 33.0 377.8 NAP NAP NAP NAP
Quartile 
25-75%
NAP 2.3-8.0 16.0-37.5 17.3-23.7 28.9-45.0 246.9-608.5 NAP NAP NAP NAP
Abbreviations - M: male; F: female; (+) presence; (-) absence; BMI: body mass index; TBSA: total burn surface area; CLcr: creatinine clearance; Quartile 
(25-75%); NAP: not applicable.
plasma concentrations for more than 40% of the dosing 
interval (Ikawa et al., 2008).
Data analysis
Statistical data analysis was carried out using 
GraphPad Prism Version 4.0 (GraphPad Software 
Corporation, San Diego, USA). P-values below 0.05 were 
considered to be significant. Quantitative variables were 
described using central tendency and dispersion measures.
RESULTS AND DISCUSSION
Experimental
Several drug measurements have been reported 
previously for imipenem in biological matrices by applying 
microbiological techniques (Pietroski et al., 1991) and 
chromatographic methods such as LC-UV (Buckley 
et al., 1992; Belzeberg et al., 2004; Ebey, Boucher, 
Pieper, 1988; Garcia-Capdevila et al., 1997; Gravallese 
et al., 1984; Kurihara, Kizu, Hori, 2008; Legrand et al., 
2008;) and LC-MS/MS (Xu et al., 2009). With regard to 
the drug assay for imipenem dose adjustment, LC-UV 
was preferred by its relative low cost relative to routine 
LC/MS/MS drug plasma measurements.
Peaks monitored at 300 nm were eluted at 5.5 min 
and 11.7 min, respectively for IS and imipenem. The 
total time required for each chromatographic run was 10 
minutes to guarantee the high selectivity and specificity; 
chromatograms are presented in Figure 1. The specificity 
of the bioanalytical method was guaranteed once the 
endogenous compounds were eluted, up to 4.5 minutes of 
chromatographic run time; consequently, no peaks were 
co-eluted with the analyte or its internal standard in the 
analytical run.
When considering plasma purification, ultrafiltration 
is a more suitable assay technique than the precipitation 
of plasma proteins for free-drug plasma monitoring in 
clinical laboratories (Buckley et al., 1992; Dailly et al., 
2011; Ebey, Boucher, Pieper, 1988; Garcia-Capdevila et 
al., 1997; Gravallese et al., 1984; Verdier et al., 2011) or 
liquid-liquid extraction (Dailly et al., 2003).
Validated method parameters for the quantification 
of imipenem in plasma according to FDA guidance (FDA, 
2001) are shown in Table II.
For the bioanalytical method, linearity was 
determined in the range of 0.25-100.0 mg/mL, and data 
were expressed by the intercept and the slope of the linear 
function as the mean, standard error of the mean (SEM) and 
linear coefficient of determination (r2) as follows: intercept 
0.0146 (SEM: 0.0183), slope 0.0273 (SEM: 0.0004) 
and r2: 0.998. Based on plasma analysis (250 mL) in 
10 replicates, the lower limit of detection was 0.12 mg/mL, 
and the lower limit of quantification was 0.25 mg/mL.
The linearity of the LC-UV measurements data 
obtained in the present study (0.25 up to 100.0 µg/mL) 
is superior or comparable to those previously reported 
(Buckley et al., 1992; Belzeberg et al., 2004; Dailly et 
al., 2011; Ebey, Boucher, Pieper, 1988; Garcia-Capdevila 
et al., 1997; Gravallese et al., 1984; Verdier et al., 2011). 
Additionally, the selectivity and specificity for imipenem 
measurements in plasma extracts were guaranteed by 
the detection of the analyte at 300 nm, as previously 
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recommended (Buckley et al., 1992; Dailly et al., 2011; 
Garcia-Capdevila et al., 1997; Verdier et al., 2011).
The bioanalytical method of therapeutic drug plasma 
monitoring, pharmacokinetic study and dose adjustments 
by PK/PD modelling in pediatric patients showed good 
sensitivity, absolute and relative recoveries, linearity and 
stability, with acceptable accuracy and precision (Table II). 
Thus, good sensitivity for plasma imipenem measurements 
was obtained in the study as a consequence of high drug 
recovery, an essential factor for drug analyses in small 
plasma volumes that clearly contributes to reducing 
volume in blood sampling. 
Additionally, good drug plasma stability was 
demonstrated after three consecutive thawing/freezing 
FIGURE 1 - Chromatographic profile of imipenem in plasma purified extract, run time 15 min (A): High drug concentration 
 (100.0 mg/mL) plus ceftriaxone (IS); (B) Medium drug concentration (20.0 mg/mL) plus IS; (C) Low drug concentration (4.0 mg/mL) 
plus IS; (D): Blank plasma plus IS; retention times obtained were 5.7 min for for ceftriaxone (IS) and 11.7 min for imipenem.
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cycles on the bench; in addition, the post processing stability 
was guaranteed at room temperature up to 24 hours for 
purified extracts on the rack of auto sampler (Table II).
In general ,  blood sampling for  laboratory 
measurements is mainly a limiting factor for drug plasma 
monitoring in children; consequently, lower volumes for 
drug plasma measurements in pediatric patients would be 
an additional advantage.
TABLE II - Confidence limits of bioanalytical method for imipenem plasma measurements
Parameter Unit Confidence Limits
Linearity (n=3) µg/mL 0.25-100.0
Linear regression (n=3 curves) r2: 0.9974
LLOD: 0.12 µg/mL (n=10) RSD 18.95
LLOQ: 0.25 µg/mL (n=10) RSD 14.86
Recovery
Absolute (n=10) analite/IS % 93.0/64.2
Relative (n=10) analite % 144.9
Precision/within-day (n=9) RSD (mean: 2.0)
80 µg/mL 5.3
40 µg/mL 6.7
1.0 µg/mL 5.8
Precision/between-day (n=27) RSD (mean: 2.3)
80 µg/mL 6.5
40 µg/mL 7.2
1.0 µg/mL 8.3
Accuracy/within-day (n=9) % (bias: 1.49%)
80 µg/mL 93.4
40 µg/mL 90.1
1.0 µg/mL 91.3
Accuracy/between-day (n=27) % (bias: 1.65%)
80 µg/mL 95.2
40 µg/mL 94.7
1.0 µg/mL 91.7
Stability /thawing cycles SE% 
Cycle 1 (n=12) 6.6
Cycle 2 (n=12) 4.4
Cycle 3 (n=12) 3.5
Stability/ short term SE%
40 µg/mL (n=3) 8.2
20 µg/mL (n=3) 7.9
0.6 µg/mL (n=3) 9.0
Stability/ post-preparative SE%
40 µg/mL (n=3) 7.2
20 µg/mL (n=3) 7.3
0.6 µg/mL (n=3) 6.9
Abbreviations: Relative Standard Deviation (RSD), standard deviation of mean (SD), systematic error (SE%), Internal standard 
(IS), LLOD: lower limit of detection; LLOQ: lower limit of quantification.
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Therapeutic drug monitoring
Imipenem plasma monitoring was performed in six 
pediatric burn patients, covering 10 sets of plasma levels. 
The investigated pharmacokinetics of a dosage of 2 g daily 
each 6 hours are described in Table III. Additionally, drug 
efficacy was evaluated by the previously reported PK/
PD correlation (Zhanel et al., 2007; Ikawa et al., 2008). 
Free-fraction drug plasma concentrations were maintained 
above the MIC within the time interval (fT>MIC), 
expressed as a percentage, and imipenem effectiveness 
is guaranteed at 40%fT>MIC. PK/PD modelling was 
investigated; the estimated data for the predictive index 
are described in Table III.
In critically ill adult burn patients, extensive changes 
in drug kinetic disposition were reported for many drugs, 
including imipenem (Weinbren, 1999; Belzeberg et al., 
2004; Blanchet et al., 2008). The pharmacokinetics of 
imipenem in adults have been described by Dailly et 
al. (2003); the changes in burn patients were related to 
an increased distribution volume, with a consequent 
prolongation of the biological half-life (Drusano et al., 
1984). In addition, a prolongation of biological half-life 
is expected if a decrease in drug plasma clearance and an 
increase in the distribution volume of critically ill patients 
occurs (Belzeberg et al., 2004).
The pharmacokinetic data for imipenem obtained 
in pediatric burn patients investigated in the present study 
varied greatly from data previously reported for septic 
adult burn patients and critically ill adult patients (Dailly 
et al., 2003; Belzeberg et al., 2004). Because kinetic 
disposition is quite different between adult patients and 
pediatric patients due to differences in body size, fluid 
compartments and drug elimination by urinary excretion 
or drug metabolism (Onishi et al., 2005), these data may 
agree with the previous studies.
PK/PD data obtained in the present study were based 
on in vitro microbial susceptibility testing (MIC data) 
of pathogens isolated from blood, fluids or secretions 
collected from pediatric burn inpatients and measured 
as part of routine clinical practice in the hospital Central 
Laboratory. In addition, if the MIC hospital data were not 
available on time, the PK/PD results were estimated based 
on available data (EUCAST, 2013).
Then, according to Figure 2, drug effectiveness 
was obtained in 100% of the plasma sets based on MIC 
hospital data obtained up to 2 mg/L, considering hospital 
Gram-positive or Gram-negative pathogens isolated from 
fluids or secretions of each patient. In contrast, imipenem 
effectiveness was reduced by 20% for Gram-positive 
pathogens (Enterococcus faecium, Enterococcus faecalis; 
MIC: 4 mg/L), with unchanged drug effectiveness against 
TABLE III - Imipenem pharmacokinetics and PK/PD correlation in burn children (n=6)
Parameters Pharmacokinetics (10 sets) PK/PD Correlation (10 sets) 13 MIC values
Patient allocation t(1/2)b (h)
CLT 
(mL/min.kg)
Vdss 
(L/kg) 0.5 mg/L 1 mg/L 2 mg/L 4 mg/L
#1 (set 1) 1.3 1.4 0.16 100 100 100 99
#1 (set 2) 0.5 2.4 0.10 70 61 53 36
#2 1.7 0.9 0.14 100 100 100 100
#3 0.8 3.8 0.26 100 104 90 63
#4 (set 1) 2.4 1.4 0.30 100 100 100 100
#4 (set 2) 1.6 13.1 1.78 100 94 74 34
#5 (set 1) 1.9 1.9 0.32 100 100 100 100
#5 (set 2) 4.8 6.4 2.68 100 100 100 100
#5 (set 3) 1.0 2.2 0.19 100 100 100 79
#6 0.4 5.5 0.17 91 85 78 65
Median 1.45 2.3 0.23 100 100 100 89
IQ (25/75%) 0.85-1.85 1.5-5.1 0.16-0.32 100-100 96-100 81-100 64-100
%TA (40%fT>MIC) NAP NAP NAP 100% 100% 100% 80%
Abbreviations and symbols - t(1/2)b: biological half-life; CLT: total body clearance; Vdss: apparent volume of distribution; TA: Target 
attainment; MIC: minimum inhibitory concentration; fT>MIC: percentage of the dosing interval that free drug plasma concentration 
remains above the MIC; NAP: not applied; IQ: Quartile (25-75%).
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Gram-negative pathogens (MIC 0.25 - 2 mg/L) relative to 
the Eucast database.
Imipenem (2 g daily, 0.5 hour infusion of 0.5 g every 
6 to 8 hours) provides sufficient drug exposure in the 
pediatric burn patients investigated in the present study 
according to data reported previously in critically ill adult 
patients (Dailly et al., 2003; Xu et al., 2009).
PK/PD data obtained for pediatric burn patients were 
estimated based on the percentage of the dose interval 
that the drug plasma concentration was maintained 
above the MIC, and the time-dependent imipenem 
effectiveness criterion was considered to be 40% 
fT>MIC, as recommended by Ikawa et al. (2008). Drug 
effectiveness against isolated pathogens during the 
antimicrobial susceptibility testing reached MIC values 
of 2 mg/L for patients in all sets investigated.
CONCLUSION
The bioanalytical method validated for imipenem 
plasma measurements by LC presented several 
advantages, such as simplicity, rapidity, specificity 
and selectivity and low required plasma volume, 
with acceptable confidence limits related to linearity, 
sensitivity and stability for the drug plasma assay. The 
method was appropriate for drug plasma measurements 
focused on drug efficacy to treat sepsis described in 
severe pediatric burn patients. A high PK/PD target 
for imipenem was attained in burned children. Finally, 
despite the altered pharmacokinetics for imipenem 
in pediatric burn patients, drug effectiveness was 
guaranteed in all sets investigated for isolated strains 
(MIC 2 mg/L) receiving the recommended daily dose 
(2 g) at a dose regimen of 0.5 g 4 times a day.
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